Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | ANPEP | P15144 | 3/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.36 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.35 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515720 | 1.00 | SLC7A5 (0.41) | SLC7A5LARS1ENPEPSCN9AANPEP | |
| SCHEMBL29010766 | 0.88 | SLC7A5 (0.45) | SLC7A5LARS1SCN9AANPEPRNPEP | |
| SCHEMBL29010817 | 0.88 | SLC7A5 (0.45) | SLC7A5LARS1SCN9AANPEPRNPEP | |
| SCHEMBL2193200 | 0.88 | SLC7A5 (0.45) | SLC7A5LARS1SCN9AANPEPRNPEP | |
| SCHEMBL7318989 | 0.88 | SLC7A5 (0.45) | SLC7A5LARS1SCN9AANPEPRNPEP | |
| SCHEMBL21625553 | 0.88 | SLC7A5 (0.45) | SLC7A5LARS1SCN9AANPEPRNPEP | |
| SCHEMBL28057635 | 0.85 | SLC7A5 (0.42) | SLC7A5LARS1SCN9AANPEPRNPEP | |
| SCHEMBL9797642 | 0.82 | SLC7A5 (0.40) | SLC7A5LARS1SCN9AANPEPRNPEP | |
| SCHEMBL7557893 | 0.82 | SLC7A5 (0.40) | SLC7A5LARS1SCN9AANPEPRNPEP | |
| SCHEMBL1795666 | 0.82 | SLC7A5 (0.40) | SLC7A5LARS1SCN9AANPEPRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11692169-B2 | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells | CELLECTIS (FR) | 2023-07-04 | — | — | US | disclosed |
| US-20230192857-A1 | INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS | WALTER & ELIZA HALL INST MEDICAL RES (AU) | 2023-06-22 | — | — | US | disclosed |
| US-20220178938-A1 | BIOMARKERS AND METHODS FOR PREDICTING PRETERM BIRTH | SERA PROGNOSTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220073931-A1 | ANTISENSE OLIGONUCLEOIDES OF GLUTATHIONE S-TRANSFERASES FOR CANCER TREATMENT | ATSO CORP AFFAIRS S A DE C V (MX) | 2022-03-10 | — | — | US | disclosed |
| US-20200407682-A1 | CELLS FOR IMMUNOTHERAPY ENGINEERED FOR TARGETING ANTIGEN PRESENT BOTH ON IMMUNE CELLS AND PATHOLOGICAL CELLS | CELLECTIS (FR) | 2020-12-31 | — | — | US | disclosed |
| US-20190317107-A1 | BIOMARKERS AND METHODS FOR PREDICTING PRETERM BIRTH | SERA PROGNOSTICS INC (US) | 2019-10-17 | — | — | US | disclosed |
| US-20180172696-A1 | BIOMARKERS AND METHODS FOR PREDICTING PRETERM BIRTH | SERA PROGNOSTICS INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20170166981-A1 | BIOMARKERS AND METHODS OF USE THEREOF | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE | 2017-06-15 | — | — | US | disclosed |
| US-20170146548-A1 | BIOMARKERS AND METHODS FOR PREDICTING PRETERM BIRTH | SERA PROGNOSTICS INC (US) | 2017-05-25 | — | — | US | disclosed |
| US-9493522-B2 | Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-15 | — | — | US | disclosed |
| EP-3004141-A1 | HISTONE DEACETYLASE ( HDAC) BIOMARKERS IN MULTIPLE MYELOMA | Acetylon Pharmaceuticals, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2972308-A2 | BIOMARKERS AND METHODS FOR PREDICTING PRETERM BIRTH | Sera Prognostics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150309047-A1 | CIRCULATING PROTEOLYTIC BIOMARKERS OF CELL DEATH AND METHODS FOR THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-10-29 | — | — | US | disclosed |
| WO-2014197471-A1 | HISTONE DEACETYLASE ( HDAC) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
| US-20140287950-A1 | BIOMARKERS AND METHODS FOR PREDICTING PRETERM BIRTH | SERA PROGNOSTICS, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140287948-A1 | BIOMARKERS AND METHODS FOR PREDICTING PRETERM BIRTH | SERA PROGNOSTICS, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2014144129-A2 | BIOMARKERS AND METHODS FOR PREDICTING PRETERM BIRTH | SERA PROGNOSTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140024539-A1 | BIOMARKERS AND METHODS OF USE THEREOF | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2014-01-23 | — | — | US | disclosed |
| US-20120028266-A1 | DISCOVERY OF CANDIDATE BIOMARKERS OF IN VIVO APOPTOSIS BY GLOBAL PROFILING OF CASPASE CLEAVAGE SITES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-02 | — | — | US | disclosed |
| EP-0456758-A1 | ANAPHYLATOXIN-RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 1991-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192857-A1 | INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS | IL2, ILF2, CD74 | SLC7A5 3093/4885LARS1 3030/4885ENPEP 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.